Healthcare Industry News: Caris Diagnostics
News Release - September 15, 2009
Caris Diagnostics Appoints Thomas T. Spalding to Senior Vice President, Chief Marketing OfficerIRVING, Texas and PHOENIX, Sept. 15, 2009 -- (Healthcare Sales & Marketing Network) -- Caris Diagnostics ("Caris Dx"), a leading provider of integrated anatomic pathology and oncology testing services, including molecular profiling and hematopathology, today announced the appointment of Thomas T. Spalding as Senior Vice President, Chief Marketing Officer. Mr. Spalding will be responsible for all corporate marketing, communications, portfolio management, consumer marketing and strategic branding.
Mr. Spalding spent over 18 years with Johnson & Johnson, where he served most recently as Worldwide Vice President, Marketing for J&J's oncology diagnostics company Veridex, L.L.C. In this capacity, Mr. Spalding was responsible for strategy and marketing efforts for CellSearch(R) and GeneSearch(R) cancer diagnostic products.
"Tom is a superb addition to the Caris Dx management team. He brings a proven track record of successfully commercializing innovative, molecular-based diagnostics," said David D. Halbert, Chairman and CEO of Caris Dx. "His skill set and depth of experience will help ensure broader awareness and adoption of Caris' own expanding suite of proprietary molecular testing technologies, Target Now(TM), Target GI Colon(TM) and other products in the pipeline. We believe that these targeted treatment options are vital to ensuring that physicians and patients can select more efficacious treatment options that improve outcomes and lower payer costs. Tom will play a central role in crafting and executing on this important mission."
"The promise of personalized medicine is quickly becoming a reality, and cutting-edge molecular and related diagnostic technologies will be key to the paradigm shift," Mr. Spalding added. "Caris Dx is poised to emerge as an industry leader as this transition occurs, and I am eager to leverage my experience, expertise and industry contacts to help ensure Caris delivers the next generation of personalized testing services to doctors and patients around the globe."
During his tenure at Johnson & Johnson, Mr. Spalding held leadership positions and commercial roles spanning multiple functions, geographies and disease specialties. He earned his Bachelor of Arts from the College of the Holy Cross in Worcester, Massachusetts, and his Masters in Business Administration from the Boston College Carroll Graduate School of Management.
About Caris Diagnostics
Caris Dx is a U.S.-based biosciences company specializing in the development and commercialization of clinically-validated molecular diagnostics and anatomic pathology services primarily in the fields of oncology, dermatopathology, hematopathology and gastrointestinal pathology. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowships and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Dx also offers advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to assist physicians in their treatment of cancer and other complex diseases. Currently, Caris Dx receives and analyzes biopsies for more than 2,700 patients per day, referred by more than 2,500 physicians nationally. Formed in 1996, the company is headquartered in Irving, Texas and operates four laboratories: Irving, Texas; Phoenix, Arizona (2 sites) and Newton, Massachusetts. Additional information is available at www.carisdx.com.
Source: Caris Diagnostics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.